Princeton, New Jersey – April 18, 2016 – Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization (Otsuka) commend the recent announcement from President Obama that he will establish an inter-agency Mental Health and Substance Use Disorder Parity Task Force to better ensure compliance with and implementation of requirements related to mental health and substance use disorder parity. Mental health disorders present a unique challenge for patients and their healthcare providers to find treatments that best address the symptoms of their diseases and help support better outcomes. Otsuka hopes that the establishment of the Parity Task Force will allow even more Americans to fully access the treatment options available to them. As an organization with deep commitment to helping patients living with serious mental illness, Otsuka supports these efforts to ensure that individuals have access to the coverage for mental health treatment and protections that the law intends. 

About Otsuka America Pharmaceutical, Inc.

Otsuka America Pharmaceutical, Inc. (OAPI) is an innovative, fast-growing healthcare company that commercializes Otsuka-discovered and in-licensed products in the U.S., with a strong focus on neuroscience, oncology, cardio-renal, and medical devices. For more information, visit www.otsuka-us.com. OAPI is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989. OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd., a global healthcare company with the corporate philosophy: 'Otsuka-people creating new products for better health worldwide.' Otsuka Pharmaceutical is a leading firm in the challenging area of mental health and also has products and research programs for several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate more powerfully than words how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka Pharmaceutical and its affiliates employ approximately 30,000 people globally, and the company welcomes you to visit its global website at: http://www.otsuka.co.jp/en/index.php. 

About Otsuka Pharmaceutical Development & Commercialization, Inc.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) is an innovative, fast-growing healthcare company that discovers and develops new compounds that address unanswered medical needs and advance human health.  With a strong focus on neuroscience, oncology, and cardio-renal treatments, OPDC is dedicated to improving the health and quality of human life.  For more information, visit http://www.otsuka-us.com. OPDC is a subsidiary of Otsuka America, Inc. (OAI), a holding company established in the U.S. in 1989.  OAI is wholly owned by Otsuka Pharmaceutical Co., Ltd. The Otsuka Group employs approximately 42,000 people globally and its products are available in more than 80 countries worldwide. Otsuka welcomes you to visit its global website at: http://www.otsuka.co.jp/en/index.php.  Media:Kimberly WhitefieldCorporate CommunicationsOtsuka America Pharmaceutical, Inc.                           kimberly.whitefield@otsuka-us.com+1 609 535 9259 April 2016     01US16EUC0020